PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemiaElevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer CellsCD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling.Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.Overview of the Use of Murine Models in Leukemia and Lymphoma Research.Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.The emerging role of immune checkpoint inhibition in malignant lymphoma.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.Tumor-derived exosomes modulate PD-L1 expression in monocytes.Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.
P2860
Q26768154-8F88EB52-C413-4946-AD52-8EEB7C40715FQ26773053-2DB5B40C-3A3B-495A-A50D-BF0A6096CA4BQ28076071-78BE95B9-7381-4210-9FAE-40BC2DD44301Q33621881-89749A7A-D3AF-45F5-A24E-FFC7DB5BD0A5Q33823270-8E276FEC-CC20-43A3-9EB2-CCA2C43B94CAQ36245171-642A60A4-3BDA-4D8B-8AC4-7371C2028E25Q36296595-86A68252-5C2E-49A7-9141-C0672497D8D0Q36298565-EBFA4192-626E-4411-A8EF-590422E544A0Q36522770-2B85CAB7-4924-4C96-B5EC-A0DD836C4667Q36651344-9C704C77-D491-48AF-AA3B-FF5EE2B4E022Q37303319-2A0A22A5-C7C9-406A-B98D-24CCD9761AA2Q37422094-7E55BCD5-246A-4BEE-850F-6A66C72E4B6AQ37457945-6C2106A5-D73A-4A41-8C88-9D6E30FAC11FQ37605306-30A1AB26-96A2-4E01-A00B-FA9A11A9A20CQ38550810-FFC2DDC7-B61C-4B49-92F6-AD4313DC344CQ38738661-DFFBEDC6-660E-4873-9E5A-2BA20C33E3A6Q38749909-24FD915D-C197-4BB2-8E15-D6A21BF5F7F4Q38752567-AB51C8E8-CAC6-4809-9942-EDDF8B5C8440Q38791036-AA595228-A125-46AD-A09C-3C3C1E7213BCQ38818283-676D2FF9-A48A-4D74-A21C-72753699F5E2Q38945853-4CECB8C3-DE56-4EA4-B80B-EA0BFB2562BFQ39055861-AC248414-D5F2-4E2B-AFD1-1E58947A541EQ39092611-5151C4CA-A158-4450-A8D1-27AC0573A323Q39420466-DA8931DC-D42C-41CD-914E-8AB15139CFCCQ39538318-948A49CC-0112-4C98-BEEB-F863DB3397DFQ40369611-6FBD5CE5-58D4-4612-8CAA-F07BE93CE8E7Q40928223-8037556D-5EBE-433A-AE34-BEB34BC7EA73Q41264795-744B39C7-8315-43E2-90C2-8AA28CDCF9F4Q46011813-0E20B8CF-B702-4D36-A0F0-548C4D3009E6Q46329110-92821C91-7E33-4164-BFD2-5C4E01332EF6Q47134535-BCB57A60-51E5-4A2B-8137-B4AEB3032C14Q47329066-D95C54B2-49CC-4E11-844D-6E6416DD919DQ47424027-8809C702-EEBD-449E-89D2-8D37FDB3360DQ47434135-D88B39D8-D598-4576-AF8E-4D04E076205EQ48187234-7A774062-4DE4-456C-9AFD-BCEC121CBA92Q48525241-7AF2628B-2533-4095-B797-4D8D2E5979E3Q49961097-29218179-D203-4B6A-9D81-D7458BF39A10Q50028314-C88291E7-A6A4-42FE-9EEC-85B1C84B508CQ50716088-26A20017-5B61-4681-8801-BE7887A2A398Q52897863-4FA1324B-CEAA-465D-A0B3-04180D24F6FD
P2860
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@ast
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@en
type
label
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@ast
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@en
prefLabel
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@ast
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@en
P2093
P2860
P1433
P1476
PD-L1 checkpoint blockade prev ...... f chronic lymphocytic leukemia
@en
P2093
Andrew James Clear
Bola Hanna
Fabienne McClanahan
John G Gribben
Martina Seiffert
Shaun Miller
P2860
P304
P356
10.1182/BLOOD-2015-01-622936
P407
P577
2015-03-23T00:00:00Z